Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07521384 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy

Study acronym: MuSE-INSIGHT
StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Healing Hope International
6 trials monitored
See all monitored trials
Stroke
3,531 trials monitored
See 153 trials at risk
Dementia
1,978 trials monitored
See 106 trials at risk
Parkinson's Disease
1,459 trials monitored
See 68 trials at risk
and 2 more diseases
This prospective observational study collects real world data on participants receiving regenerative therapies administered internationally and delivered intranasally via the Kurve Therapeutics ViaNase device. The study does not assign treatment. Participants are enrolled after receiving, or electing to receive, therapy as part of routine clinical care outside the study. Participants are observed in one of three cohorts based on the therapy received: MuSE cell derived exosomes, MuSE stem cells, or combination therapy. The objective is to evaluate safety, tolerability, and changes in inflammatory biomarkers and clinical outcomes over time in a real world setting. The study also evaluates changes in inflammatory biomarkers, including serum tumor necrosis factor alpha (TNF-α), to better understand the biological effects of these therapies.
Trial Details
NCT Number NCT07521384
Lead Sponsor Healing Hope International
Collaborators: Kurve Technology Inc.
Conditions
(from sponsor)		 Traumatic Brain Injury, Cerebral Palsy, Hypoxic Ischemic Encephalopathy, Neurologic Disorders, MS (Multiple Sclerosis), Alzheimer Dementia (AD), Parkinson Disease (PD), Stroke +1 more
Related terms Alzheimer Disease, Autistic Disorder, Brain Injuries, Traumatic, Cerebral Palsy, Hypoxia-Ischemia, Brain, Multiple Sclerosis, Nervous System Diseases, Parkinson Disease, Stroke
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov